Levormeloxifene

Levormeloxifene
	IUPAC name 1-(2-{4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy}ethyl)pyrrolidine
Identifiers
CAS number	31477-60-8
PubChem	35805
ChemSpider	32935
UNII	9512UKZ352
ChEMBL	CHEMBL301327
Jmol-3D images	Image 1
	SMILES O(c1ccc(cc1)[C@@H]3c4c(OC([C@H]3c2ccccc2)(C)C)cc(OC)cc4)CCN5CCCC5 ;
	InChI InChI=1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1 ; Key: XZEUAXYWNKYKPL-WDYNHAJCSA-N InChI=1/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1; Key: XZEUAXYWNKYKPL-WDYNHAJCBQ ;
Properties
Molecular formula	C30H35NO3
Molar mass	457.604
	(verify) (what is: /?); Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
	Infobox references

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Levormeloxifene is an experimental selective estrogen receptor modulator that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials.^[1] It is the enantiomer of ormeloxifene.

[edit] References

^ Ravn P, Nielsen TF, Christiansen C. (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. doi:10.1080/00016340500345691. PMID 16532904.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.